Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/08—Peptides having 5 to 11 amino acids
  • A61K38/085—Angiotensins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
  • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
  • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention is characterized by the process of preparation of formulations of the heptapeptide Angiotensin-(1-7) and its similar ones, agonists and antagonists, using preferentially the ciclodext ⁇ ' nes, and derivatives, lipossomes, and biodegradable polymers, and/ or mixtures of those systems and/ or of the derived products. It is also characterized by the identification of the ligand-receptor interaction between the G-coupled receptor, MAS, and angiotensin-(1-7) and its analogues using or not encapsulated formulations, as a target for research and therapeutic interventions in cardiovascular, renal reproductive, dermatological, tumoral, neurological and blood diseases.
• the aging of the population is already an important factor for the increase in the incidence of heart failure: while 1 % of the individuals in the age range of 25 to 54 years old present heart failure, among the more seniors the incidence is very larger, reaching about 10% in those individuals with more than 75 years (Kaannel W. B. et. al. Changing epidemiological features of cardiac failure. Br. Heart J 1994; 72 (suppl):S3-S9).
• the heart failure by its clinical characteristic is a restrictive disease, that reduces the quality of the patients' life with its worsening and, in the advanced forms, is characterized as a malign disease with mortality rate above 60% in the first year, even nowadays (Oliveira, M.T. Clinical characteristics and patients' prognostic with advanced congestive heart failure.
• Hypertension is a complex, multifactorial, of high prevalence disease responsible for countless deleterious effects and high morbimortality (Kaplan, N. M. Blood pressure the cardiovascular risk factor: prevention ant treatment. JAMA. 275:1571-1576, 1996).
• Several studies aimed for the evaluation of the effectiveness of its control in the population in general and in special groups have been developed, in order to better understand its course.
• the control of the normal level of blood pressure without wide intervention with no pharmaceutical drugs of the associated risk factors can reduce or even avoid the benefits of the long term treatment of arterial hypertension in the reduction of the mortality, in general, as for coronary disease (Wilson, P. W. et. al. Hypertension, the risk factors and the risk of cardiovascular disease. Raven Press. 94-114).
• Hypertension is the pathology that more contributes to the cardiovascular aterosclerose (The fifth Report of the Joint National Committee on detection, evaluation, and treatment of High Blood Pressure. National Institute of Health (VJNC). Arch. Intern. Med. 153:154-181, 1994). According to statistics, of each four Americans, one is, or will be, hypertensive, and it is estimated 4,78 million people with heart failure. Every year 400 thousand new cases are diagnosed, provoking 800 thousand hospitalizations, with an expense of US$ 17,8 billion of dollars in the treatment.
• the renin-angiotensin system is responsible for the regulation of the arterial pressure, cardiovascular homeostase and hydroelectrolite balance, as in physiological as in pathological conditions (Krieger, E. M.; Santos, R. A. S. Angiotensins - physiologic aspects. Hypertension, 1 :7-10,1998).
• Angiotensin II (Ang II) is the main peptide of RAS, possessing several actions: vasopressor, stimulator of the synthesis of adrenal steroides, proliferative effect (fibroblasts, smooth muscle of the vasculature) and hypertrophic (cardiomiocites).
• Angiotensin-(1-7) is a biologically active peptides of the angiotensin "family", being formed by a pathway indenpendent of the ACE.
• Ang I processing by endopeptidases or Ang II by prolil-peptidases or carboxi-peptidases can generate the heptapeptide, Ang-(1-7).
• Ang-(1-7) can be hydrolysed by amino- peptidases generating Ang-(2-7) and Ang-(3-7).
• the hydrolysis of Ang-(1-7) by ACE originates Ang-(1-5) (Santos, R. A. S.; Campagnole-Santos, M. J.; Andrade,- S. P. Angiotensin-(1-7): an update. Regulatory Peptides, 91 :45-62, 2000).
• Ang-(1-7) and Ang II are the main effectsors of the RAS.
• two important characteristics differentiate Ang-(1-7) from Ang II: the first one possesses highly specific biological actions and its formation pathway is independent of ACE (Santos, R. A. S.; Campagnole-Santos, M. J.; Andrade, S. P. Angiotensin-(1-7): an update. Regulatory Peptides, 91:45-62, 2000).
• hypertension treatment not only seeks for the fall expenses, but as well as the prevention of end-organ damages, through modifications of life quality and the use of medications, when necessary (The Fifth Report of The Joint National Committee on detection, evaluation, and treatment of High Blood Pressure. National Institute of Health (VJNC). Arch. Intern. Med. 153:154-181 , 1994).
• anti-hypertensive drugs is indicated when patients do not respond to the alterations in lifestyle for a period of three to six months, and in the presence of end-organs damage (left ventricular hypertrophy, myocardic ischemia, stroke, or hypertensive retinopathy). All patients with systolic arterial pressure above 180 mmHg or diastolic arterial pressure above 110 mmHg should be submitted to pharmacological treatment, independent of the presence of another (Report the Canadian Hypertension Society. Consensus Conference. 3. Pharmacological treatment of essential hypertension. Xan. Med. Assoc. J. 149 (3): 575-584, 1993).
• the diuretics can be divided in three categories: thazidics, loop diuretics and the potassium savers.
• the thazidics and analogues include chlorothiazides and hidroclorotiazide, which induce in the first days of treatment a 10-15% of decrease in the arterial pressure mainly due to a decrease in the extracellular volume and an increase in the diuresis and natriuresis. After six months, the blood volume and cardiac output return to baseline levels and the decrease in arterial pressure is maintained by a decrease in peripheral vascular resistance (Frolich, E. Current Approaches in the treatment of Hypertension, 405-469). These drugs are habitually used as monotherapy and the give best results in black patients and, at low doses, in the old patients.
• the calcium channel blockers are being used for at least 25 years (Frolich, E. D. Current Approaches in the Treatment of Hypertension, 405-469, 1994). They can be classified in two major groups, according to its pharmacological actions: those that have larger action in the conduction of the stimulus, such as Verapamil and Diltiazem, and those that present a predominant vasodilator action, as those derived from diidropirinicos (Nifedipine and others) (Frolich, E. D., Hypertension. Adult Clinical Cardiology Self Assessment Program (ACCSAP), 6: 3-19, 1995). They present as collateral effects edema of inferior members and tachycardia.
• ACCSAP Advanced Clinical Cardiology Self Assessment Program
• the main action of the ACE inhibitors is to inhibit the conversion of angiotensin I in to angiotensin II.
• Teprotide the first ACE inhibitor clinically used, exerted its anti-hypertensive action only when it was administered by intravenous route, because it was inactive when given orally, what have limited its employment.
• ACE is an enzyme with multiple actions, i.e., that it acts in several substrate.
• ACE renin-like peptide
• Ang I circulating and tissue Ang-(1-7)
• Ang II circulating and tissue Ang-(1-7)
• the circulating concentration of this peptide is similar to Ang II concentration and it has been shown that it increases after inhibition of ACE. This increase can be due to both the increase in its precursor (Ang I) and the decrease in its degradation by ACE (Santos, R. A. S.; Campagnole-Santos, M. J.; Andrade, S. P. Angiotensin-(1-7): an update.
• ACE inhibitors are excellent when administered as monotherapy, since they induce a relatively fast fall in arterial pressure in 60 to 70% hypertensive patients. (Ganong, W. Neuropeptides in cardiovascular control. J. Hypertens 2 (suppl 3): 15-22, 1984). In addition, they are in general well tolerated, but its use can cause collateral effects and adverse reactions, some of which are relatively serious, among them angiodema, cutaneous eruptions and dry coughs (8 to 10%).
• the first attempts to develop Ang II antagonists are from the beginning of the 70's decade and they were concentrated on the development of peptides similar to Ang II.
• the first antagonist was saralasina, 1-sarcosina, 8-isoleucina angiotensin II, that was followed by others. However, they did not have clinical acceptance, because they presented partial agonistic activity.
• S-8307 and S8308 were developed the first two selective antagonists for the ATi receptor of non-peptidic characteristic. However, eventhough they were highly specific and without agonistic activity, they presented a weak bind to Ang ITS receptors.
• Angiotensin-(1-7), (Asp-Arg-Val-Tyr-lle-His-Pro) and its derivative one [Sar 1 ]-Ang-(1-7) antagonize Ang II pressor effect in man (Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh and, Umemura S, Ishii M.
• Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 2000; 35:998-1001 ) and mice (Bovy PR, Trapani AJ, McMahon EG, Palomo M.
• the carboxy-terminus truncated analogue of angiotensin II [Sar 1 ]-angiotensin ll-(1-7)-amide provides an entry to the new class of angiotensin II antagonists. J Med Chem. 1989; 32:520-522). The contraction produced by Ang II in isolated arteries of rabbits and humans is also reduced by angiotensin-(1-7) (Bovy PR, Trapani AJ, McMahon EG, Palomo M. The carboxy-terminus truncated analogue of angiotensin II [Sar 1 ] angiotensin ll-(1-7)-amide, provides an entry to the new class of angiotensin II antagonists.
• Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999; 34(2):296-301 ). Until very recently, the receptor(s) responsible for the transduction of the Ang-(1-7) response had not been identified and many possibilities were raised regarding Ang-(17) signal transduction.
• vasodilatation produced by Ang-(1-7) in the afferent arterioles of rabbits, the Ang-(1-7) pressor effect in the RVLM, the vasodilation produced in the mesenteric microcirculation in vivo are completely blocked by the administration of A-779, and are not affected by the selective Ang II antagonists.
• Other studies using bovine endothelial cells, dog coronary arteries, SHR aorta, human epithelial fibroblasts, human heart fibroblasts and kidney slices have supported the evidences for the existence of specific receptors of Ang-(1-7) that can be blocked by the A-779. (Santos, RAS; Campagnole-Santos, MJ.; Andrade, SP. Angiotensin-(1-7): an update. Regulatory Peptides, 91:45-62, 2000).
• A-779 and its analogues such as Sar1-D-Ala 7-Ang-(1-7) (Bovy PR, Trapani AJ, McMahon EG, Palomo M. THE carboxy-terminus truncated analogue of angiotensin II [Sari] angiotensin ll-(1-7)-amide, provides an entry to the new class of angiotensin II antagonists. J Med Chem. 1989; 32:520- 522.), and the D-Pro7-Ang-(1-7) (Naves-Santos, V., Khosla, M. C, Oliveira, R. C, Campagnole-Santos, M. J., Lima, D.
• Ang-(1-7) acts inside the RAS as a contraregulatory peptide of this system, acting at multiple points (Ferrario CM, Chappell MC, Dean RH, Iyer SN. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis.
• Ang-(1-7) decreases angiogenesis and cellular proliferation (Machado, RDP, Santos, RAS, Andrade, SP. Mechanisms of angiotensin-(1-7) induced inhibition of angiogenesis. Am J Physiol, 280: 994-1000, 2001. Rodgers K, Xiong S, Felix J, Rotates N, Espinoza T, Maldonado S, Dizerega G. Development of angiotensin-(1-7) the in the agent to accelerate dermal repair. Wound Repair Regen, 9: 238-247, 2001) presenting therefore a potential for the treatment of lesions.
• Ang-(1-7) can act as an ACE inhibitor in the amino- terminal domain of the enzyme, in which it acts as substrate, as well in the c- terminal domain in which it acts as an inhibitor (Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erd ⁇ s EG. N-domain-specific substrate and C- domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto- ACE. Hypertension. 1998; 31 :912-917. Tom B, Of Vries R, Saxena PR, Danser AHJ. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C - and N-domain blockade.
• IC50 for inhibition of ACE is approximately 1 micromolar (Chappell MC, Pirro NT, Sykes THE, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin- converting enzyme. Hypertension. 1998; 31 (part 2):362-367. Paula, RD, Lima, CV, Britto, RR, Campagnole-Santos, MJ, Khosla, MC, Santos, RAS. Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides, 20:493-500, 1999.
• Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man.
• Angiotensin-(1-7) is a modulator of the human renin-angiotensin system.
• Angiotensin-(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertension 1994; 12:1377-1381), and 2) altering the signalling mechanisms of Ang II effects, possibly by altering the availability of intracellular calcium (Chansel D, Vandermeerch S, Andrzej T, Curat C, Ardaillou R. Effects of angiotensin IV and angiotensin-(1-7) on basal angiotensin ll-stimulated cytosolic Ca+2 in mesangial cells. Eur J Pharmacol. 2001; 414:165-175).
• a third mechanism for which Ang-(1-7) can antagonize the Ang II deleterious effects on the cardiovascular system are the potentiation of the bradykinin effects (Paula, RD; It Rasps, CV, Khosla, MC, Santos, RAS.
• Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in concious rats. Hypertension, 26: 1154-1159, 1995. Li P, Chappell MC, Ferrario CM, Brosnihan KB.
• Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997; 29 (part 2):394-400).
• Bradykinin is an endogenous peptide with potent vasodilatatory action (Rocha and Silva, M, Beraldo, WT, Rosenfeld, G. Bradykinin, the hypotensive and smooth muscle stimulating factor releases from shapes globulin by snake venoms and by trypsin. Am. J. Physiol. 156, 261-273, 1949). It has also been described beneficial actions of bradykinin in the heart (Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res. 1999; 43:549-561). Ang-(1-7) potentiate the effects of bradykinin, in vessels (Paula, R.
• Angiotensin-(1-7) potentiates the hypotensive ffect of bradykinin in concious rats. Hypertension, 26: 1154-1159, 1995. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin- induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension.
• a particular drug could be chemically modified in order to alter its properties such as biodistribution, pharmacokinetics and solubility.
• Various methods have been used to increase the solubility and stability of drugs, among them the use of organic solvents, their incorporation within emulsions or liposomes, the adjustment of pH, their chemical modifications and their complexation with the cydodextrins.
• the cydodextrins are oligosacharides cyclic family, which include six, seven or eight units of glucopyranose. Due to sterics interactions, the cydodextrins, CD's, form a cycle structure in the shape of a (cone truncado) with an internal cavity apolar.
• the cydodextrins hosts form complexes with various hydrophobic guests in their cavity.
• the CD's have been used for the solubilization and encapsulation of the drugs, perfumes and fragrances as described by Szejtli, J., Chemical Reviews, (1998), 98, 1743-1753. Szejtli, J., J. Mater. Chem., (1997), 7, 575-587. According to detailed studies of toxicity, mutagenecity, teratogenecity and carcinogenecity about the cydodextrins, described in [Rajewski, R.A., Stella, V., J.
• the known cyclodextrin derivatives can be classified according to their polarity, size, biological activity, etc. As for their practical uses are classified as follows: 1. Carriers (solubilizers, stabilizers) for biologically active substances; 2. Enzyme models; 3. Separating agents (for chromatography or batch-processes); 4. Catalysts and additives (as detergents, viscosity modifiers, etc), L. Szente and J. Szejtli, Adv. Drug Deliv. Rev. 36 (1999), 17.
• the CD's are moderately soluble in water, methanol and ethanol and readily soluble in polar solvents, such as the dimetyl sulfoxide, dimetylformamide, N,N- dimetylacetamide e piridine.
• DDS drug delivery system
• various kinds of high performance carrier materials are being developed to deliver the necessary amount of drug to the targeted site for a necessary period of time, both effi ently and precisely.
• Cydodextrins, biodegradable or non biodegradable polymers, liposomes, emulsions, multiple emulsions are potential candidates for such a role, because of their ability to alter physical, chemical, and biological properties of guest molecules
• polymer microcapsules Besides the cydodextrins, a number of drug delivery systems have been investigated, including polymer microcapsules, microparticles, liposomes and emulsion. Many of these are prepared from synthetic biodegradable polymers such as polyanhydrides and poly(hydroxy acids). In these systems the drugs incorporate in a polymeric microspheres, which release the drug inside the organism, in small and controlled daily doses, during days, months or until years.
• polymers can be chose from: poly(2-hidroxi-ethylmetacrilate), polyacrilamide, polymer from lactic acid (PLA), from glicolic acid (PGA), and the respective ones co-polymers, (PLGA) and the poly(anidrides), as described by Tamada and Langer, J. Biomater. Sci. Polym. Edn, 3(4):315-353.
• a formulation of the present invention can also include other components such as a pharmaceutical acceptable excipient.
• formulation of the present invention can be formulated in an excipient that the animal to be protected can tolerate. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability of buffers.
• Standard formulation can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection or oral formulation.
• Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles, nanoparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres and transdermal delivery systems, implantable or not.
• biocompatible polymers include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles, nanoparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres and transdermal delivery systems, implantable or not.
• biocompatible polymers include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles,
• Liposomes are lipid vesicles that include aqueous internal compartments in which molecules, for example drugs, are encapsulated with the objective of reaching a controlled release of the drug after administration in individuals.
• the procedure of Bangham produces "ordinary MLVs", that present unequal solute distributions among the aqueous compartments and, consequently, differences of osmotic pressure.
• Lenk et al. (Pat US 4,522,803; US 5,030,453 and US 5,169,637), Fountain et al.
• Satisfactory lipids include for example, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, cardiolipin, cholesterol, phosphatidic acid, sphingolipids, glycolipids, fatty acids, sterols, phosphatidylethanolamine, polymerizable lipids in their polymerized or non-polymerized form, mixture of these lipids.
• the composition of the liposomes can be manipulated such as to turn them specific for an organ or a cell type.
• the targeting of liposomes has been classified either on the basis of anatomical factors or on the basis of the mechanism of their interaction with the environment.
• the anatomical classification is based on their level of selectivity, for example, organ-specific or cell-spedfic. From the point of view of the mechanisms, the targeting can be considered as passive or active.
• Sterically stabilized liposomes are characterized by a reduced rate of elimination from the blood circulation [Lasic and Martin, Stealth Liposomes, CRC Press, Inc., Boca Raton, Fla. (1995)].
• PEG-liposomes present a polyethylene glycol polymer conjugated to the head group of some phospholipid that reduces their interadion with plasma proteins, such as opsonins, and reduces the rate of their uptake by cells.
• the diameter of the vesicles should be below 200 nm, the number of units in PEG of approximately 2.000 and the proportion of Pegylated lipid from 3 to 5 mol% [Lasic and Martin, Stealth Liposomes, CRC Press, Inc., Boca Raton, Fla. (1995); Woodle et al., Biochim. Biophys. Acta 1105:193-200 (1992); Litzinger et al., Biochim. Biophys. Acta 1190:99-107 (1994); Bedu Addo et al., Pharm. Res. 13:718-724 (1996)].
• the active targeting involves alteration of liposomes through their association with a liguand, such as a monoclonal antibody, a sugar, a glycolipid, protein, a polymer or by changing the lipid composition or the liposome size to target them to organs and cells different from those which accumulate conventional liposomes.
• a liguand such as a monoclonal antibody, a sugar, a glycolipid, protein, a polymer or by changing the lipid composition or the liposome size to target them to organs and cells different from those which accumulate conventional liposomes.
• Liposome-based vehicles have been proposed for a large variety of pharmacologically active substances, including antibiotics, hormones and antitumoral agents [Medical applications of liposomes (D.D. Lasic, D. Papahadjopoulos Ed.), Elsevier Science B.V., Holland, 1998].
• Ang-(1-7) and its analogues have great potential for study and treatment of several diseases including cardiovascular disorders.
• Another important aspect related RAS is related to the clear need of amplification of the knowledge about its physiologic actions that can propitiate the development of new therapeutic strategies.
• the conventional way of administration of most of the drugs anti-hipertensive especially biologically active peptides, as the angiotensins and derivatives suffers limitations due to the short half-life of peptides.
• the present invention is characterized by the use of liposomes, cydodextrins and biodegradable polymers as controlled release systems of the angiotensins and derivatives to increase their bioavailability, the duration and intensity of their biological effects.
• the formulation of the present invention is characterized by the use of the mixture of excipients pharmaceutically acceptable for Ang-(1-7) and/or analogues.
• Excipients examples include water, saline solution, buffered phosphate solutions , the solution of Ringer, dextrose solution, the solution of Hank, biocompatible saline solutions with or without polyethylene glycol.
• Non aqueous vehicles, as fixed oils, sesame oil, ethyl-oleate, or triglicerides can also be used.
• Other useful formulations include agents capable to increase the viscosity, as carboximetilculose of sodium, sorbitol, or dextran
• the excipients can also contain smaller amounts of additives, such as substances that increase isotonicidade and chemical stability of substance or buffers.
• buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include timerosal, m- or o-cresol, formalin and benzyl-alcohol.
• the formulation state can be liquid or solid.
• the excipients can indude dextrose, human serum albumin, preservatives, etc. for which water or sterile saline solution can be added before the administration.
• the present invention is also characterized by the preparation of controlled release systems containings Ang-(1-7) and/or its analogues for interaction ligand-receptor with the G Protein-coupled receptor, MAS.
• Satisfactory systems of controlled release include, but are not limited to, the ciclodextrines, biocompatible polymers , biodegradable polymers, other polymeric matrixes, capsules, micro-capsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, lipossomes, lipoesferes, and systems of transdermic administration .
• Other compositions of controlled release of the present invention include liquids that, when submitted the temperature changes, form a solid or a gel in situ.
• the MAS receptor (Young, D., Waitches, G., Birchmeier, C, Fasano, O., and Wigler, M. (1986). Isolation and charaderization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 45: 711-719) was initially described as an angiotensin II receptor (Jackson, T.R., Blair, A.C., Marshall, J., Goedert, M. & Hanley, M.R. The mas oncogene encodes an angiotensin receptor. Nature 335, 437-440 (1988)), however subsequent studies showed that this hypothesis was not right (Ambroz, C, Clark, A.J.L.
• the mas oncogene enhances angiotensin-induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. Biochem. Biophys. Acta 1133, 107-111 (1991)). This protein is expressed in the brain (Bunnemann, B., Fuxe, K., Metzger, R., Mullins, J., Jackson, T.R., Hanley, M.R. & Ganten, D. Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci. Lett. 114, 147-153 (1990)) and in other tissues. There is no description in the literature of an interaction of MAS with angiotensin-(1-7) or its analogues.
• the present invention is characterized by the obtention of systems of controlled release of the heptapeptide Angiotensin - (1-7) and/or its derivatives, using the ciclodextrines and/or its derivatives , that decrease the degradation of the peptide in the treatment gastrointestinal (TGI), meaning larger biodisponibility of the peptide in the biological system.
• TGI treatment gastrointestinal
• the present invention it is characterized by the obtention of controlled release systems of the heptapeptide Angiotensin-(1-7) and/or of its analogues, using biodegradable polymers , lipossomes or mixtures of those systems with ciclodextrines, which increase the biodisponibility of the peptides.
• Example 1 heptapeptide Angiotensin-(1-7) or its analogues, agonists and antagonists associated to the ciclodextrines or theirs derivatives, to biodegradable polymers or to lipossomes, was not described.
• the present invention can be understood better through the following examples: Example 1
• This example describes the preparation of Ang-(1-7) in the encapsulated form in sterically stabilized liposomes and the improvement of the bioavailability of Ang-(1 -7) when administered in that form.
• Ang-(1-7) in liposomes was performed according to Kirby and Gregoriadis [Biotechnology 2:979-984 (1984)] and was followed by the extrusion of the liposome suspension through polycarbonate membranes with a pore size of 200 nm [Nayar et al. Biochim. Biophys. Acta. 986:200-206 (1989)]. Peptide-containing liposomes were then separated from non-encapsulated peptide by dialysis and finally sterilized by filtration through sterile membranes of 0.22 micrometers.
• the amount of encapsulated peptide was determined using the intrinsic fluorescence of Ang- (1-7). Encapsulation was achieved with an efficiency of 12% and a peptide/lipid ratio of 0.03 (p/p).
• the size of liposomes was determined through the dynamic light scattering technique. A mean vesicle diameter of 0.19 micrometer was determined.
• Ang-(1-7)-containing liposomes were unilaterally microinjected (35 ng of Ang-(1-7) in 200 nL) in the rostroventrolateral medulla (RVLM) of Wistar rats with a needle (30 G) that was inserted slowly in the brain. Empty liposomes (LEmp) were also similarly microinjected at the same lipid dose.
• the mean arterial blood pressure (MAP) was determined by telemetry 4 days before and 12 days after microinjection in freely moving undisturbed animals. The microinjection of LAng produced a significant pressor effect during day-time that was maintained for 5 days. The highest MAP was obtained on day 3 (114 ⁇
• day-time MAP was significantly higher in LAng group than in Lemp group on day 1 , 2 and 3.
• Night-time MAP in contrast to day-time MAP, was not affected significantly by the microinjection of LAng.
• PVA 1%
• the mixture is centrifuged by 2 to 3 times, and washed three times with water to remove the surface-adsorbed PVA and finally resuspended in 2 mL of water and freeze- dried. Then the solid microspheres were characterized through the thermal analysis and scanning electron microscopy SEM.
• the microspheres DSC curve shown a vitreous transition similar to which it was observed to the PLGA polymer.
• the respectively SEM micrographs shown 50 microns of particles size. It is still verified the porous surface of the microspheres.
• To determine the peptide encapsulation was accomplished by radioimunoensaio [Neves et al., Biochem. Pharmacol. 50:1451-1459 (1995)]. It was obtained 15% of peptide encapsulation.
• the kinetics profile shown the 60% of peptide release approximately in 8 h and about 90% in 48 h.
• the preparation is made in equimolar proportions of cyclodextrin and Ang-(1-7).
• ⁇ -cyclodextrin and or its derivatives is dissolved in water using stirring and heating.
• angiotensin-(1- 7) is added to the aqueous solution.
• the mixture is frozen in liquid nitrogen and submitted tc the lyophilization process, obtaining a dry solid.
• the solid obtained is the submitted to the physical-chemistry characterization using the FT infrared spectroscopy, thermal analysis (TG/DTG and DSC), X-ray diffraction and 1H and 13C NMR spectroscopy and T1 relaxation times.
• Example 4 This example describes the identification of an interaction between angiotensin-(1-7) and its analogues with the G protein-coupled receptor, MAS.
• the Ang_(1-7) binding in kidney slices of wild type mice was displaced by the analogues D- Ala 7 -Angiotensin-(1-7) e D-Pro 7 -Angiotensin-(1-7).
• the functional test for the absence of binding in knockout mice was made using the water diuresis model (administration of 5% of the body weight, of H 2 0).
• Ang-(1-7) treatment (4pmol/10g BW) in wild type mice produced a reduction of the urine volume (antidiuresis).
• MAS knockout mice the antidiuretic effect of Ang-(1-7) was absent.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Dermatology (AREA)
• Vascular Medicine (AREA)
• Nanotechnology (AREA)
• Immunology (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Medical Informatics (AREA)
• Biotechnology (AREA)
• Emergency Medicine (AREA)
• Crystallography & Structural Chemistry (AREA)
• Obesity (AREA)
• General Engineering & Computer Science (AREA)
• Biophysics (AREA)
• Hospice & Palliative Care (AREA)
• Neurosurgery (AREA)
• Reproductive Health (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=3948119

Family Applications (1)

Country Status (10)

Cited By (15)

Families Citing this family (19)

Citations (3)

Family Cites Families (39)

• 2001
  • 2001-11-05 BR BRPI0105509A patent/BRPI0105509B8/pt not_active IP Right Cessation
• 2002
  • 2002-11-05 JP JP2003541528A patent/JP2005511577A/ja active Pending
  • 2002-11-05 KR KR10-2004-7006892A patent/KR20040089078A/ko active Application Filing
  • 2002-11-05 WO PCT/BR2002/000156 patent/WO2003039434A2/en active Application Filing
  • 2002-11-05 EP EP20110160834 patent/EP2356995A3/en not_active Withdrawn
  • 2002-11-05 EP EP02780983.9A patent/EP1450842B1/en not_active Expired - Lifetime
  • 2002-11-05 US US10/494,758 patent/US7723304B2/en not_active Expired - Lifetime
  • 2002-11-05 KR KR1020107024591A patent/KR101246608B1/ko active IP Right Grant
  • 2002-11-05 CN CNB028240138A patent/CN100525830C/zh not_active Expired - Fee Related
  • 2002-11-05 AU AU2002349190A patent/AU2002349190A1/en not_active Abandoned
  • 2002-11-05 MX MXPA04004313A patent/MXPA04004313A/es active IP Right Grant
  • 2002-11-05 CA CA2466232A patent/CA2466232C/en not_active Expired - Fee Related
• 2010
  • 2010-03-01 US US12/715,363 patent/US20100158995A1/en not_active Abandoned
  • 2010-09-27 JP JP2010215646A patent/JP2011037868A/ja not_active Ceased

Patent Citations (3)

Non-Patent Citations (17)

Also Published As

Similar Documents

Legal Events